Ipca Laboratories (IPCALAB) Q3 24/25 earnings summary

Executive summary

• Domestic formulation business grew 13% for the quarter, outpacing the overall pharma market growth of 7.4% and ranking 16th by IQVIA, fastest among top 20 players.

• Standalone net total income for Q3 FY25 rose 10% year-over-year to Rs. 1,680.09 crores; consolidated net total income up 9% to Rs. 2,265.48 crores.

• Standalone net profit for Q3 FY25 increased 95% year-over-year to Rs. 267.56 crores; consolidated net profit up 38% to Rs. 248.14 crores.

• Chronic segment growth was 17.1% versus IPM growth of 9.7%; acute segment growth was 8.7% versus market growth of 6%.

• Market share improved by 11 basis points to 2.05% as of December 2024, with six brands among the top 300 in India.

Financial highlights

• Standalone Q3 FY25 EBITDA margin rose to 24.25% from 18.52% in Q3 FY24; consolidated Q3 FY25 EBITDA margin at 19.87%, up from 16.1%.

• Gross margin reached a record high, driven by improved product mix and higher ROW market sales, with material cost ratio dropping to 27.62% in Q3 FY25 from 32% in the prior year.

• API business grew 12% for the quarter; overall formulation business grew 6%.

• Standalone EPS for Q3 FY25 was Rs. 10.55 (after exceptional items), up 95% year-over-year; consolidated EPS was Rs. 9.78, up 38%.

• Effective tax rate expected at 27%-28% for FY25.

Outlook and guidance

• FY25 standalone EBITDA margin expected in the 23%-24% range, above initial guidance of 21%.

• Consolidated EBITDA margin for FY25 projected at 19.18%-19.5%, exceeding guidance of 18%.

• API business expected to grow 8%-10% going forward.

• Domestic business expected to grow at 1.5x the Indian pharma market (IPM) rate.

• Margins anticipated to improve by 100-150 basis points over the next 3-4 years due to operational leverage and productivity gains.